{
  "docId": "019de075-d132-769f-97bd-4a840dd24899",
  "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 55,
  "pageCount": 56,
  "prevPage": 54,
  "nextPage": 56,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a split-screen diagram to contrast physiological affinity vs high affinity in the context of FcRn-mediated antibody recycling.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/55",
  "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899",
  "deckJsonHref": "/decks/019de075-d132-769f-97bd-4a840dd24899.json",
  "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-55",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.63,
        "x": 0.02,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Comparison of 1st gen mAb vs Spyre mAb recycling pathways via FcRn",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c4b7ab0c-5f0b-4d03-943a-156052b72827",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.67,
        "y": 0.35
      },
      "kind": "list",
      "text": "Spyre mAbs designed to be recycled back into circulation more readily; Drug exists at much higher levels for longer duration of effect; Fewer injections decrease patient burden and can improve compliance and penetration",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0706dc15-9d07-4b5e-b647-5f0f9a0a5332",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "SOURCE: Adapted from Ko S et al BioDrugs 2021",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8fa518ed-3030-4e5b-92f9-cee6027a5d0a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "Spyre mAbs employ proven half-life extension technology",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a29b739d-8e2c-4f2d-be46-fcdb60670a0e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "ad59d031-a01e-4d24-b04f-e7b9543b9617",
      "evidence": "diagram/process: Comparison of 1st gen mAb vs Spyre mAb recycling pathways via FcRn",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "60cfd52e-2ba2-4706-a3d0-78bcb57af41b",
      "evidence": "The diagram illustrates the biological process of antibody recycling.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 56,
      "from": 45,
      "beatId": "a269a747-0743-41c8-a64a-96220e98956c",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "The document outlines the potential impact and next steps for Spyre's pipeline.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}